Biomarker Solution Center
Scientific thought leadership and guidance across our extensive global laboratory testing capabilities. Delivering customized, end-to-end biomarker solutions throughout the drug development life cycle.
Globally integrated, multidisciplinary and collaborative approach for biomarkers
Implement customized biomarker solutions and co-development of diagnostic solutions
Gain innovative and state-of-the-art biomarker platforms and global laboratory testing capabilities
Leverage the scientific experience of our biomarker experts and drive clinical and commercial success
Biomarker Solutions and Precision Medicine
Biomarkers are at the epicenter of today’s drug development and the pursuit of personalized medicine. They help drive patient identification and stratification, and also help define disease biology, identify mechanism of action and understand the pharmacokinetics and pharmacodynamics relationship of your drug. These benefits can lead to successful drug development; however, you need these biomarker insights early in the process. Our Biomarker Solution Center (BSC) leaders work with you to develop biomarker strategies and solutions, from discovery through commercialization, to support your drug development needs. We can identify gaps and provide mitigation strategies to build a customized strategy that integrates biomarkers across your development plan. Such a customized solution will help you meet critical endpoints faster and accelerate speed to market.
Unrivaled access to laboratory testing technologies
Across Covance and LabCorp, our extensive global laboratory testing capabilities range from standard clinical laboratory and safety testing to esoteric and complex biomarker testing including exploratory / fit-for-purpose to GLP/GCLP and CAP/CLIA. Our comprehensive suite of biomarker capabilities span the spectrum of biomarker testing – including DNA, RNA and proteins – from single analyte to multiplex testing. We leverage a wide array of platforms and technologies, including Next Generation Sequencing, transcriptional profiling, RNA sequencing, flow cytometry, serum testing of proteins and anatomic pathology. Our BSC team can also work with you in transferring proprietary assays dependent on your needs. Together, we can leverage these capabilities to customize assay solutions to help optimize the drug development plan.
An experienced approach to biomarker development
Leverage our extensive, multidisciplinary knowledge in biomarkers and therapeutic area expertise to help define and design a comprehensive biomarker strategy tailored specifically to your development needs. Our thought leaders engage with you early in the process to identify and build the right biomarker solution across multiple therapeutic areas including cardiovascular, metabolic, immunology and oncology
Suso J. Platero, PhD
Head, Biomarker Solution Center
Global Leader, Precision Medicine, Covance
Dr. Suso Platero leads the Biomarker Solution Center, providing clients with biomarker consultation and strategy that leverages both Covance and LabCorp laboratories resources to aid in the development of biomarker delivery. He draws on 20+ years of experience with contract research organizations, diagnostic and pharmaceutical industries and academia, as well as with federal agencies and key opinion leaders in oncology and immuno-oncology.
Dr. Platero has contributed to the discovery of biomarkers and their application in clinical trials as well as the development of biomarkers to support companion diagnostics (CDx) and recently helped develop a companion diagnostic for a drug that was approved by the FDA in 2019. He served as the editor of the book, Molecular Pathology in Drug Discovery and Development, has authored numerous articles and holds four U.S. patents.
Akanksha Gupta, PhD
Head of Immunology, Biomarker Solution Center
Dr. Akanksha Gupta leads the immunology therapeutic team for the Biomarker Solution Center, a team that delivers biomarker solutions and strategy to clients, leveraging the laboratory resources of both Covance and LabCorp. Her strategic leadership provides scientific direction on biomarker strategies integrating innovative technologies, emerging scientific knowledge, clinical feasibility and regulatory requirements for a precision medicine approach across multiple therapy areas including immuno-inflammation, immuno-oncology, respiratory, dermatology and other auto-immune disorders.
Dr. Gupta draws more than 15 years of pharmaceutical industry experience in drug development, translational research and supporting development strategies for early to late stage assets. She shares her experience as author or co-author of more than 30 peer-reviewed research publications, abstracts and patent submissions.
Katherine T. Landschulz, PhD
Head of Cardiovascular / Metabolic Disease, Biomarker Solution Center
Dr. Katherine Landschulz joined Covance in 2010 after 13 years of experience with three major pharmaceutical companies where she supported programs spanning discovery through Phase III. At Covance, she supports both biotech and large pharmaceutical companies with biomarker selection and strategy development, laboratory placement for method development and qualification/validation, feasibility study design and advises on the use of translational and exploratory biomarker data in drug development.
Dr. Landschulz has a wide range of experience in drug discovery and development, genomic and proteomic biomarker assay development, translational biomarkers, clinical pharmacogenomics and biomarker strategies for Diabetes/CV. She is the holder of two U.S. patents and has co-authored dozens of publications on across a wide range of therapeutic areas.
Maria J. Prendes, PhD, MS
Head of Oncology, Biomarker Solution Center
Dr. Maria Prendes leads the Biomarker Solution Center oncology therapeutic team and works with clients to guide the selection, characterization and development of biomarkers for their clinical trials. Her responsibilities also include supporting companion diagnostics (CDx) development efforts.
Specializing in the fields of immuno-oncology, cancer genetics, cancer biology and molecular oncology, Dr. Prendes has more than 15 years of experience in drug development where she directed research for the identification of new clinical biomarkers in oncology as well as designed, developed and characterized antibodies against specific biomarker targets to be used as therapeutic agents and for development of CDx assays. She is the holder of multiple U.S. patents and has authored and co-authored numerous journal articles.